481 related articles for article (PubMed ID: 25646108)
1. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
2. The evolution of biotechnology and its impact on health care.
Evens R; Kaitin K
Health Aff (Millwood); 2015 Feb; 34(2):210-9. PubMed ID: 25646100
[TBL] [Abstract][Full Text] [Related]
3. The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation.
Fleming JJ
Health Aff (Millwood); 2015 Feb; 34(2):271-6. PubMed ID: 25646107
[TBL] [Abstract][Full Text] [Related]
4. The roles of patents and research and development incentives in biopharmaceutical innovation.
Grabowski HG; DiMasi JA; Long G
Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
[TBL] [Abstract][Full Text] [Related]
5. Resistance to antibiotics: are we in the post-antibiotic era?
Alanis AJ
Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
[TBL] [Abstract][Full Text] [Related]
6. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
Rex JH; Outterson K
Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
[TBL] [Abstract][Full Text] [Related]
8. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
Deak D; Outterson K; Powers JH; Kesselheim AS
Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches are needed to develop tomorrow's antibacterial therapies.
Spellberg B; Bartlett J; Wunderink R; Gilbert DN
Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
[TBL] [Abstract][Full Text] [Related]
11. Innovation of novel antibiotics: an economic perspective.
McKellar MR; Fendrick AM
Clin Infect Dis; 2014 Oct; 59 Suppl 3():S104-7. PubMed ID: 25261536
[TBL] [Abstract][Full Text] [Related]
12. The antibiotic pipeline: reviving research and development and speeding drugs to market.
Luepke KH; Mohr JF
Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
[TBL] [Abstract][Full Text] [Related]
13. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
14. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
Edwards SE; Morel CM
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
[No Abstract] [Full Text] [Related]
15. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
Barton JH; Emanuel EJ
JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
[TBL] [Abstract][Full Text] [Related]
16. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
17. Into the valley of death: research to innovation.
Hudson J; Khazragui HF
Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
[TBL] [Abstract][Full Text] [Related]
18. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
19. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
